Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$24.05 +0.7%	$21.93	$12.21 ▼ $41.31	$697.78M	-0.27	643,024 shs	212,764 shs
COLL Collegium Pharmaceutical	$30.37 -0.5%	$29.22	$23.23 ▼ $42.29	$975.21M	0.64	399,305 shs	140,319 shs
ESPR Esperion Therapeutics	$1.17 +1.8%	$0.99	$0.69 ▼ $3.94	$231.89M	0.7	4.83 million shs	2.32 million shs
MRUS Merus	$53.84 +1.0%	$49.89	$33.19 ▼ $62.98	$3.73B	1	739,450 shs	222,443 shs
PRVB Provention Bio	$24.98	$24.58	$3.18 ▼ $25.00	$2.37B	2.47	2.28 million shs	218,200 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	0.00%	+7.01%	+13.74%	+29.90%	-3.43%
COLL Collegium Pharmaceutical	0.00%	+1.47%	+2.95%	+7.92%	-6.15%
ESPR Esperion Therapeutics	0.00%	+17.85%	+0.95%	-4.80%	-50.38%
MRUS Merus	0.00%	+1.60%	-3.87%	+41.28%	+1.68%
PRVB Provention Bio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANAB AnaptysBio	2.3034 of 5 stars	3.4	1.0	0.0	0.0	2.2	2.5	0.6
COLL Collegium Pharmaceutical	4.2713 of 5 stars	3.4	1.0	0.0	3.0	3.1	0.8	2.5
ESPR Esperion Therapeutics	4.2225 of 5 stars	3.4	3.0	0.0	3.9	2.6	1.7	0.6
MRUS Merus	1.8428 of 5 stars	3.6	1.0	0.0	0.0	1.4	2.5	0.0
PRVB Provention Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.80	Moderate Buy	$42.38	76.23% Upside
COLL Collegium Pharmaceutical	2.75	Moderate Buy	$43.75	44.06% Upside
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	497.78% Upside
MRUS Merus	3.14	Buy	$84.64	57.20% Upside
PRVB Provention Bio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ESPR, COLL, PRVB, ANAB, and MRUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/4/2025	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$22.00 ➝ $38.00
5/29/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
5/28/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $90.00
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
5/19/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
5/9/2025	COLL Collegium Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$36.00 ➝ $37.00
5/8/2025	MRUS Merus	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$91.00 ➝ $89.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
5/6/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$52.00 ➝ $54.00
5/1/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$40.00 ➝ $40.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$111.87M	6.31	N/A	N/A	$2.33 per share	10.32
COLL Collegium Pharmaceutical	$664.28M	1.47	$12.35 per share	2.46	$7.10 per share	4.28
ESPR Esperion Therapeutics	$332.31M	0.70	$0.02 per share	48.70	($1.97) per share	-0.59
MRUS Merus	$54.73M	68.09	N/A	N/A	$9.46 per share	5.69
PRVB Provention Bio	$12.90M	183.54	N/A	N/A	$1.40 per share	17.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$145.23M	-$4.85	N/A	N/A	N/A	-125.70%	-282.47%	-30.79%	8/4/2025 (Estimated)
COLL Collegium Pharmaceutical	$69.19M	$1.22	24.89	5.04	N/A	6.61%	99.08%	15.14%	8/6/2025 (Estimated)
ESPR Esperion Therapeutics	-$51.74M	-$0.80	N/A	N/A	N/A	-59.03%	-0.91%	-29.47%	8/11/2025 (Estimated)
MRUS Merus	-$215.33M	-$4.08	N/A	N/A	N/A	-506.73%	-35.99%	-29.83%	7/30/2025 (Estimated)
PRVB Provention Bio	-$113.57M	-$1.53	N/A	N/A	N/A	-880.69%	-103.36%	-69.08%	N/A

Latest ESPR, COLL, PRVB, ANAB, and MRUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	$1.49	-$0.01	$0.07	$174.96 million	$177.76 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million
5/5/2025	Q1 2025	ANAB AnaptysBio	-$1.30	-$1.28	+$0.02	-$1.28	$15.27 million	$27.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
PRVB Provention Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	8.25	8.25
COLL Collegium Pharmaceutical	3.30	1.08	1.01
ESPR Esperion Therapeutics	N/A	1.18	0.81
MRUS Merus	N/A	5.86	5.86
PRVB Provention Bio	0.19	1.93	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
COLL Collegium Pharmaceutical	N/A
ESPR Esperion Therapeutics	47.39%
MRUS Merus	96.14%
PRVB Provention Bio	37.39%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	33.50%
COLL Collegium Pharmaceutical	2.51%
ESPR Esperion Therapeutics	1.70%
MRUS Merus	4.57%
PRVB Provention Bio	13.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	29.38 million	19.54 million	Optionable
COLL Collegium Pharmaceutical	210	32.13 million	31.33 million	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
MRUS Merus	37	69.21 million	66.05 million	Optionable
PRVB Provention Bio	82	94.78 million	82.37 million	Not Optionable

ESPR, COLL, PRVB, ANAB, and MRUS Headlines

Recent News About These Companies

Provention finally gets FDA nod for type 1 diabetes drug teplizumab

March 9, 2025 | pharmaphorum.comP

FDA rejects Provention's type 1 diabetes drug teplizumab

November 19, 2024 | pharmaphorum.comP

Kimber Creek Ford

August 2, 2024 | cars.comC

Ann Tricklebank Biography & Movies

May 25, 2024 | tribute.caT

VOA News

May 22, 2024 | voanews.comV

Topic - Cumberland Valley School District

May 5, 2024 | washingtontimes.comW

Macrogenics Inc MGNX

December 29, 2023 | morningstar.comM

And for Wegovy's Next Trick, Full-Blown Cardiovascular Benefit Outside Diabetes

November 13, 2023 | medpagetoday.comM

Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes

October 24, 2023 | nejm.orgN

FDA sets August decision date for Provention's type 1 diabetes drug

July 23, 2023 | pharmaphorum.comP

Larry Pine Biography & Movies

June 27, 2023 | tribute.caT

Sanofi/Provention: innovative diabetes drug is a good fit

May 1, 2023 | finance.yahoo.com

Those who invested in Provention Bio (NASDAQ:PRVB) a year ago are up 456%

April 29, 2023 | finance.yahoo.com

Sanofi completes Provention Bio acquisition

April 28, 2023 | seekingalpha.com

Sanofi concludes acquisition of Provention Bio

April 28, 2023 | medicaldialogues.inM

Sanofi completes acquisition of Provention Bio, Inc.

April 28, 2023 | pharmiweb.comP

Earnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to Decline

April 27, 2023 | finance.yahoo.com

Sanofi - Aventis Groupe: Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.

April 27, 2023 | finanznachrichten.de

Provention Bio gains after HSR waiting period for Sanofi deal expired

April 26, 2023 | seekingalpha.com

Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.

April 26, 2023 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Tesla Bulls and Bears Collide: What Investors Should Know
By Sam Quirke | June 18, 2025
View Tesla Bulls and Bears Collide: What Investors Should Know

ESPR, COLL, PRVB, ANAB, and MRUS Company Descriptions

AnaptysBio NASDAQ:ANAB

$24.04 +0.17 (+0.69%)

Closing price 07/3/2025 03:45 PM Eastern

Extended Trading

$23.57 -0.47 (-1.97%)

As of 07/3/2025 04:36 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Collegium Pharmaceutical NASDAQ:COLL

$30.37 -0.14 (-0.46%)

Closing price 07/3/2025 01:48 PM Eastern

Extended Trading

$30.37 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Esperion Therapeutics NASDAQ:ESPR

$1.17 +0.02 (+1.83%)

Closing price 07/3/2025 03:42 PM Eastern

Extended Trading

$1.16 -0.01 (-0.51%)

As of 07/3/2025 04:47 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Merus NASDAQ:MRUS

$53.84 +0.51 (+0.96%)

Closing price 07/3/2025 01:04 PM Eastern

Extended Trading

$53.38 -0.46 (-0.85%)

As of 07/3/2025 04:34 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Provention Bio NASDAQ:PRVB

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time